Contineum Therapeutics, Inc.
CTNM
$11.43
-$0.10-0.87%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -17.28% | -41.93% | -67.47% | -80.82% | -360.53% |
| Total Depreciation and Amortization | 19.27% | 25.19% | 42.27% | 46.27% | 50.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 88.25% | 171.71% | 289.40% | 2,568.47% | 314.84% |
| Change in Net Operating Assets | -374.18% | -213.22% | -480.79% | 240.31% | 1,400.75% |
| Cash from Operations | -45.53% | -68.40% | -57.35% | -42.66% | -336.38% |
| Capital Expenditure | -19.81% | 55.06% | 45.97% | 43.22% | 18.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 9.06% | 94.97% | 168.48% | 82.59% | 3.84% |
| Cash from Investing | 8.84% | 94.68% | 166.94% | 82.23% | 3.98% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.87% | 3.61% | -81.44% | -99.13% | 39,791.21% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -332.14% | -- | 25.36% | 48.69% | 128.99% |
| Cash from Financing | 3.44% | 3.38% | -81.62% | -99.35% | 92.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -137.25% | 736.22% | -92.55% | -324.34% | -13.82% |